MX375426B - Direccionamiento de antagonistas de citocinas. - Google Patents
Direccionamiento de antagonistas de citocinas.Info
- Publication number
- MX375426B MX375426B MX2016000721A MX2016000721A MX375426B MX 375426 B MX375426 B MX 375426B MX 2016000721 A MX2016000721 A MX 2016000721A MX 2016000721 A MX2016000721 A MX 2016000721A MX 375426 B MX375426 B MX 375426B
- Authority
- MX
- Mexico
- Prior art keywords
- targeting
- cytokine
- cytokine antagonists
- fusion protein
- receptor
- Prior art date
Links
- 102000004127 Cytokines Human genes 0.000 title abstract 2
- 108090000695 Cytokines Proteins 0.000 title abstract 2
- 230000008685 targeting Effects 0.000 title abstract 2
- 239000005557 antagonist Substances 0.000 title 1
- 239000000430 cytokine receptor antagonist Substances 0.000 abstract 2
- 108020001507 fusion proteins Proteins 0.000 abstract 2
- 102000037865 fusion proteins Human genes 0.000 abstract 2
- 102000005962 receptors Human genes 0.000 abstract 2
- 108020003175 receptors Proteins 0.000 abstract 2
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000011664 signaling Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/56—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Transplantation (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13306045 | 2013-07-19 | ||
| PCT/EP2014/063976 WO2015007520A1 (en) | 2013-07-19 | 2014-07-01 | Targeting of cytokine antagonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2016000721A MX2016000721A (es) | 2016-09-07 |
| MX375426B true MX375426B (es) | 2025-03-06 |
Family
ID=48874233
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016000721A MX375426B (es) | 2013-07-19 | 2014-07-01 | Direccionamiento de antagonistas de citocinas. |
Country Status (11)
| Country | Link |
|---|---|
| US (5) | US9732135B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3022230B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6475712B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102305608B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN105658669A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2014292355B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2918119C (cg-RX-API-DMAC7.html) |
| IL (1) | IL243459B (cg-RX-API-DMAC7.html) |
| MX (1) | MX375426B (cg-RX-API-DMAC7.html) |
| SG (2) | SG10202010429YA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2015007520A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9492562B2 (en) * | 2012-01-20 | 2016-11-15 | Vib Vzw | Targeted human-interferon fusion proteins |
| CN105658669A (zh) * | 2013-07-19 | 2016-06-08 | 弗拉芒区生物技术研究所 | 细胞因子拮抗剂的靶向 |
| US11702477B2 (en) | 2015-11-06 | 2023-07-18 | Orionis Biosciences BV | Bi-functional chimeric proteins and uses thereof |
| US11661455B2 (en) | 2016-02-05 | 2023-05-30 | Orionis Biosciences BV | Chimeric protein comprising an interferon alpha 2mutant and a PD-L1 binding moiety |
| WO2017134301A1 (en) | 2016-02-05 | 2017-08-10 | Orionis Biosciences Nv | Clec9a binding agents |
| CN109069573B (zh) * | 2016-03-07 | 2022-04-05 | 弗拉芒区生物技术研究所 | 结合cd20的单结构域抗体 |
| US20190077871A1 (en) * | 2016-03-07 | 2019-03-14 | Vib Vzm | Cd20 binding agents and uses thereof |
| EP3455245A2 (en) * | 2016-05-13 | 2019-03-20 | Orionis Biosciences NV | Therapeutic targeting of non-cellular structures |
| CN109689087B (zh) | 2016-05-13 | 2023-04-04 | 奥里尼斯生物科学私人有限公司 | 靶向性突变干扰素-β及其用途 |
| ES2917000T3 (es) | 2016-10-24 | 2022-07-06 | Orionis Biosciences BV | Interferón-gamma mutante diana y usos del mismo |
| JP7586579B2 (ja) | 2017-02-06 | 2024-11-19 | オリオンズ バイオサイエンス インコーポレイテッド | 標的化改変型インターフェロン及びその使用 |
| CN110546160A (zh) | 2017-02-06 | 2019-12-06 | 奥里尼斯生物科学公司 | 靶向嵌合蛋白及其用途 |
| US11246911B2 (en) | 2017-02-07 | 2022-02-15 | Vib Vzw | Immune-cell targeted bispecific chimeric proteins and uses thereof |
| CN111511764B (zh) | 2017-08-09 | 2024-02-06 | 奥里尼斯生物科学有限公司 | Clec9a结合剂及其用途 |
| EP3665201A4 (en) * | 2017-08-09 | 2021-06-02 | Orionis Biosciences, Inc. | CD8 BINDERS |
| CA3069994A1 (en) | 2017-08-09 | 2019-02-14 | Orionis Biosciences Inc. | Pd-1 and pd-l1 binding agents |
| US20200354424A1 (en) | 2018-01-26 | 2020-11-12 | Orionis Biosciences, Inc. | Xcr1 binding agents and uses thereof |
| AU2019215440B2 (en) | 2018-02-05 | 2025-12-04 | Orionis Biosciences, Inc. | Fibroblast binding agents and use thereof |
| US12084497B2 (en) | 2018-08-08 | 2024-09-10 | Orionis Biosciences, Inc. | SIRP1α targeted chimeric proteins and uses thereof |
| WO2020097350A1 (en) | 2018-11-08 | 2020-05-14 | Orionis Biosciences, Inc. | Modulation of dendritic cell lineages |
| CN111499718B (zh) * | 2019-01-30 | 2022-06-14 | 复旦大学 | 人α干扰素受体结合相关位点突变体及其用途 |
| KR20220012227A (ko) | 2019-03-28 | 2022-02-03 | 오리오니스 바이오사이언시즈 인코포레이티드 | Clec9a-기반 키메라 단백질 복합체 |
| CN113767115B (zh) | 2019-03-28 | 2025-05-02 | 奥里尼斯生物科学股份有限公司 | 治疗性干扰素α1蛋白 |
| CA3139291A1 (en) | 2019-07-18 | 2021-01-21 | Jacky Vonderscher | Method for decreasing adverse-effects of interferon |
| MX2023011310A (es) | 2021-03-26 | 2023-10-05 | Innate Pharma | Anclajes de citocina para proteinas de celulas nk de union a nkp46. |
| WO2022258678A1 (en) | 2021-06-09 | 2022-12-15 | Innate Pharma | Multispecific proteins binding to nkp30, a cytokine receptor, a tumour antigen and cd16a |
| CA3218793A1 (en) | 2021-06-09 | 2022-12-15 | Laurent Gauthier | Multispecific proteins binding to nkp46, a cytokine receptor, a tumour antigen and cd16a |
| WO2022258691A1 (en) | 2021-06-09 | 2022-12-15 | Innate Pharma | Multispecific proteins binding to nkg2d, a cytokine receptor, a tumour antigen and cd16a |
| WO2024040247A1 (en) | 2022-08-18 | 2024-02-22 | Regeneron Pharmaceuticals, Inc. | Interferon proproteins and uses thereof |
| US20240067691A1 (en) | 2022-08-18 | 2024-02-29 | Regeneron Pharmaceuticals, Inc. | Interferon receptor agonists and uses thereof |
| WO2024238415A1 (en) | 2023-05-12 | 2024-11-21 | Regeneron Pharmaceuticals, Inc. | Interferon receptor antagonists and uses thereof |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0489116B1 (en) | 1989-08-22 | 1994-04-06 | Immunex Corporation | Fusion proteins comprising gm-csf and il-3 |
| US6277969B1 (en) * | 1991-03-18 | 2001-08-21 | New York University | Anti-TNF antibodies and peptides of human tumor necrosis factor |
| US5914254A (en) | 1993-08-02 | 1999-06-22 | Celtrix Pharmaceuticals, Inc. | Expression of fusion polypeptides transported out of the cytoplasm without leader sequences |
| DE69733610T2 (de) * | 1996-04-26 | 2006-05-11 | Beth Israel Deaconess Medical Center, Inc., Boston | Interleukin-15 antagonisten |
| WO2001010912A1 (en) * | 1999-08-09 | 2001-02-15 | Lexigen Pharmaceuticals Corp. | Multiple cytokine-antibody complexes |
| US20020193569A1 (en) | 2001-06-04 | 2002-12-19 | Idec Pharmaceuticals Corporation | Bispecific fusion protein and method of use for enhancing effector cell killing of target cells |
| EP1812038A1 (en) | 2004-11-18 | 2007-08-01 | VIB vzw | Fibronectin iii domain as leptin receptor antagonists |
| WO2006115800A2 (en) | 2005-04-15 | 2006-11-02 | The Regents Of The University Of California | Enhanced wound healing utilizing an anti-her2 antibody coupled to a tnf alpha |
| ES2436761T3 (es) * | 2005-06-29 | 2014-01-07 | Yeda Research And Development Co., Ltd. | Mutantes de interferón alfa 2 (IFN alfa 2) recombinante |
| EP2052081A1 (en) | 2006-08-02 | 2009-04-29 | McGill University | Fusion proteins and methods for modulation of immune response |
| WO2008124086A2 (en) | 2007-04-05 | 2008-10-16 | President And Fellows Of Harvard College | Chimeric activators: quantitatively designed protein therapeutics and uses thereof |
| JP5501222B2 (ja) * | 2007-05-11 | 2014-05-21 | アルター・バイオサイエンス・コーポレーション | 融合分子及びｉｌ−１５変異体 |
| JP2010531666A (ja) | 2007-06-26 | 2010-09-30 | ユニバーシティ オブ マイアミ | 抗体−エンドスタチン融合タンパク質及びそのバリアント |
| MX2010003099A (es) | 2007-09-21 | 2010-05-17 | Univ California | Interferon de objetivo demuestra actividades potentes apoptoticas y antitumorales. |
| US20110224407A1 (en) * | 2008-09-09 | 2011-09-15 | University Of Medicine And Dentistry Of New Jersey | Type I Interferon Antagonists |
| WO2010036918A2 (en) | 2008-09-26 | 2010-04-01 | University Of Massachusetts | Intracellular dna receptor |
| AU2009326075B2 (en) | 2008-12-08 | 2014-06-05 | Complix Nv | Single-chain antiparallel coiled coil proteins |
| AU2010285071A1 (en) | 2009-08-17 | 2012-02-02 | Roche Glycart Ag | Targeted immunoconjugates |
| US20130115189A1 (en) | 2009-09-10 | 2013-05-09 | Cytos Biotechnology Ag | Use of Interleukin-1 Beta Mutein Conjugates in the Treatment of Diabetes |
| US9534056B2 (en) | 2011-06-06 | 2017-01-03 | Immungene Inc | Engineered TAA antibody-TNFSF member ligand fusion molecules |
| CN109022465B (zh) * | 2011-10-28 | 2022-04-29 | 特瓦制药澳大利亚私人有限公司 | 多肽构建体及其用途 |
| US9492562B2 (en) * | 2012-01-20 | 2016-11-15 | Vib Vzw | Targeted human-interferon fusion proteins |
| HRP20200918T1 (hr) | 2012-03-03 | 2020-11-27 | Immungene, Inc. | Modificirane mutirane fuzijske molekule interferonskog antitijela |
| CN105658669A (zh) * | 2013-07-19 | 2016-06-08 | 弗拉芒区生物技术研究所 | 细胞因子拮抗剂的靶向 |
-
2014
- 2014-07-01 CN CN201480040656.4A patent/CN105658669A/zh active Pending
- 2014-07-01 CA CA2918119A patent/CA2918119C/en active Active
- 2014-07-01 US US14/905,348 patent/US9732135B2/en active Active
- 2014-07-01 JP JP2016526507A patent/JP6475712B2/ja active Active
- 2014-07-01 AU AU2014292355A patent/AU2014292355B2/en active Active
- 2014-07-01 MX MX2016000721A patent/MX375426B/es active IP Right Grant
- 2014-07-01 KR KR1020167002677A patent/KR102305608B1/ko active Active
- 2014-07-01 SG SG10202010429YA patent/SG10202010429YA/en unknown
- 2014-07-01 EP EP14734166.3A patent/EP3022230B1/en active Active
- 2014-07-01 WO PCT/EP2014/063976 patent/WO2015007520A1/en not_active Ceased
- 2014-07-01 SG SG11201600165WA patent/SG11201600165WA/en unknown
-
2016
- 2016-01-04 IL IL24345916A patent/IL243459B/en active IP Right Grant
-
2017
- 2017-07-06 US US15/642,989 patent/US10072059B2/en active Active
-
2018
- 2018-06-14 US US16/008,695 patent/US20180334489A1/en not_active Abandoned
- 2018-06-14 US US16/008,686 patent/US10947288B2/en active Active
-
2021
- 2021-02-09 US US17/171,433 patent/US20210238247A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3022230B1 (en) | 2019-11-06 |
| IL243459B (en) | 2019-10-31 |
| JP6475712B2 (ja) | 2019-02-27 |
| US20180057555A1 (en) | 2018-03-01 |
| WO2015007520A1 (en) | 2015-01-22 |
| AU2014292355B2 (en) | 2019-08-01 |
| JP2016529232A (ja) | 2016-09-23 |
| KR20160108292A (ko) | 2016-09-19 |
| CN105658669A (zh) | 2016-06-08 |
| US20180334489A1 (en) | 2018-11-22 |
| SG10202010429YA (en) | 2020-11-27 |
| US10947288B2 (en) | 2021-03-16 |
| US20180334488A1 (en) | 2018-11-22 |
| KR102305608B1 (ko) | 2021-09-28 |
| CA2918119A1 (en) | 2015-01-22 |
| CA2918119C (en) | 2022-11-29 |
| IL243459A0 (en) | 2016-03-31 |
| US20210238247A1 (en) | 2021-08-05 |
| US20160159875A1 (en) | 2016-06-09 |
| US9732135B2 (en) | 2017-08-15 |
| EP3022230A1 (en) | 2016-05-25 |
| MX2016000721A (es) | 2016-09-07 |
| SG11201600165WA (en) | 2016-02-26 |
| AU2014292355A1 (en) | 2016-02-04 |
| US10072059B2 (en) | 2018-09-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX375426B (es) | Direccionamiento de antagonistas de citocinas. | |
| SA518400222B1 (ar) | أجسام مضادة لـ وتركيبات tim-3 | |
| MX375441B (es) | Fusocinas que implican citocinas con una afinidad de union al receptor considerablemente menor. | |
| MX380520B (es) | Anticuerpos receptores de antitransferina y métodos de uso. | |
| PE20150891A1 (es) | Anticuerpos anti-receptor de il-13 alfa 2 y conjugados de anticuerpo farmaco | |
| PH12016500141A1 (en) | Methods of treating sporadic inclusion body myositis | |
| EA201600190A1 (ru) | Анти-prlr антитела и их применение | |
| EA201891040A1 (ru) | Конъюгаты антитела, содержащие агонисты толл-подобного рецептора | |
| GT201700102A (es) | Conjugados de anticuerpo-fármaco | |
| EA201791093A1 (ru) | Антитела к cd47, способы и применение | |
| MX2009008104A (es) | Hepcidina, antagonistas de hepcidina y metodos de uso. | |
| MX2015016304A (es) | Proteinas de union al antigeno del receptor de oncostatina m. | |
| UA107782C2 (ru) | Антагонисты рецепторов fgf-r4 | |
| EA201600141A1 (ru) | Терапевтический слитый белок | |
| EA201690633A1 (ru) | Способы и композиции, включающие комбинацию антагониста vegf и анти-ctla-4 антитела | |
| BR112018075651A2 (pt) | anticorpos anti-cd98 e conjugados anticorpo fármaco | |
| UA123202C2 (uk) | Антитіло до тау-білка і його застосування | |
| EA201491107A1 (ru) | Антитела к рецептору эпидермального фактора роста 3 (her3), направленные на домен ii her3 | |
| EP3452107A4 (en) | DNA MONOCLONAL ANTIBODIES AGAINST CHECKPOINT MOLECULES | |
| CR20130632A (es) | El anticuerpo neutralizador del receptor de prolactina mat3 y su uso terapéutico | |
| EA201690388A1 (ru) | Новые производные унциаламицина, способы их синтеза и их применение в качестве противоопухолевых агентов | |
| MX377190B (es) | Uso de un anticuerpo anti-il6r para el tratamiento de la artritis reumatoide. | |
| MA38413A1 (fr) | Anticorps pan-elr+ cxc chimiokine | |
| MX366178B (es) | Proteinas de btnl3, acidos nucleicos, y anticuerpos y los usos de los mismos. | |
| MX385589B (es) | RÉGIMEN DE DOSIFICACIÓN PARA ANTAGONISTAS DE MAdCAM. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HC | Change of company name or juridical status |
Owner name: SULZER MANAGEMENT AG |
|
| FG | Grant or registration |